bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Do you find yourself mishearing lyrics? I do all the time. I recently learned the word for this phenomenon—mondegreen—and how ...

The Somerville gene therapy company was once among the highest-profile biotechs in the Boston area, but now has agreed to be taken private for a small fraction of the amount at which it was once ...

For a full version of this story, visit STAT. Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $ ...

Songwriter John Lennon's audacious claim in 1966 that the band was "more popular than Jesus" incited a severe backlash from ...

To celebrate the beginning of spring in the Gaelic calendar, ornithologist Seán Ronayne is across the schedule on RTÉ lyric fm with a new series to discuss the distinct bird songs, melodies and ...

To celebrate the beginning of spring in the Gaelic calendar, ornithologist Seán Ronayne is across the schedule on RTÉ lyric fm with a new series to discuss the distinct bird songs, melodies and ...

Song of Songs is a mosaic of love poems which has a loosely defined plot. The original text does not include indications for each speaker, but most translations include notes naming the Bride and ...

Singer Lady Blackbird has always had a huge, rafter-shaking voice. Born Marley Munroe in New Mexico, Lady Blackbird will perform at the Musical Instrument Museum in Phoenix.

From my observations in the market, I believe one of the most interesting prospects these days for investors to consider is Blue Bird Corporation (NASDAQ:BLBD). The school bus manufacturer is ...

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.

Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...